Head to Head Review: Graybug Vision (NASDAQ:GRAY) and Kinnate Biopharma (NASDAQ:KNTE)

Graybug Vision (NASDAQ:GRAYGet Rating) and Kinnate Biopharma (NASDAQ:KNTEGet Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

Analyst Ratings

This is a summary of current ratings and recommmendations for Graybug Vision and Kinnate Biopharma, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Graybug Vision 0 2 2 0 2.50
Kinnate Biopharma 0 0 6 0 3.00

Graybug Vision currently has a consensus target price of $2.50, suggesting a potential upside of 147.52%. Kinnate Biopharma has a consensus target price of $36.17, suggesting a potential upside of 151.51%. Given Kinnate Biopharma’s stronger consensus rating and higher probable upside, analysts plainly believe Kinnate Biopharma is more favorable than Graybug Vision.

Profitability

This table compares Graybug Vision and Kinnate Biopharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Graybug Vision N/A -57.68% -53.86%
Kinnate Biopharma N/A -34.09% -29.41%

Risk and Volatility

Graybug Vision has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Comparatively, Kinnate Biopharma has a beta of -0.3, suggesting that its stock price is 130% less volatile than the S&P 500.

Insider & Institutional Ownership

49.9% of Graybug Vision shares are owned by institutional investors. Comparatively, 97.7% of Kinnate Biopharma shares are owned by institutional investors. 7.9% of Graybug Vision shares are owned by insiders. Comparatively, 37.9% of Kinnate Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Graybug Vision and Kinnate Biopharma’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Graybug Vision N/A N/A -$35.82 million ($1.65) -0.61
Kinnate Biopharma N/A N/A -$89.76 million ($2.40) -5.99

Kinnate Biopharma is trading at a lower price-to-earnings ratio than Graybug Vision, indicating that it is currently the more affordable of the two stocks.

Summary

Kinnate Biopharma beats Graybug Vision on 7 of the 11 factors compared between the two stocks.

About Graybug Vision

(Get Rating)

Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.

About Kinnate Biopharma

(Get Rating)

Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.

Receive News & Ratings for Graybug Vision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Graybug Vision and related companies with MarketBeat.com's FREE daily email newsletter.